Biomarkers In Chemotherapy-Induced Peripheral Neurotoxicity: Better Tools And Understanding
This pilot study will attempt to establish the feasibility of using tissue oxygen
measurements as a potential biomarker for chemotherapy-induced peripheral neuropathy (CIPN).
Thirty (30) subjects scheduled to begin taxane-based chemotherapy for breast tumor will be
assigned to receive an India ink injection under the skin of the foot. The ink will be used
to make up to five (5) 45-minute "electron paramagnetic resonance" (EPR) oximetry readings
prior to the start of chemotherapy. Subjects will undergo electrophysiologic assessments
including electromyography and nerve conduction studies, in addition to a neurological
examination prior to the start of chemotherapy. Subjects will have the EPR oximetry readings,
electrophysiologic tests, and neurological examination two more times: at the halfway point
of their chemotherapy treatment -- or at the onset of CIPN symptoms -- and again after
chemotherapy has been completed.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.